In plain terms: EGCG (Epigallocatechin Gallate / Green Tea Extract) has some human trial evidence supporting it, but the evidence is not yet strong enough for EBL to call it established. It is worth knowing about and worth discussing with your clinician.
EGCG (Epigallocatechin Gallate / Green Tea Extract)
The evidence as the record states it
LDL cholesterol: Zheng et al. (Am J Clin Nutr, 2011; PMID 21715508): meta-analysis of 14 randomized controlled trials, 1,136 subjects: green tea intake lowered LDL cholesterol by 2.19 mg/dL and total cholesterol by 7.20 mg/dL; it did not measure blood pressure. Kim et al. (J Am Diet Assoc, 2011; PMID 22027055): independent meta-analysis of 20 trials, 1,415 participants, catechins at 145 to 3,000 mg/day for 3 to 24 weeks, LDL 5.30 mg/dL lower, no change in HDL or triglycerides. Momose et al. (Int J Food Sci Nutr, 2016; PMID 27324590): systematic review of 17 trials restricted to EGCG at 107 to 856 mg/day in healthy adults, LDL 9.29 mg/dL lower. Xu et al. (Nutr J, 2020; PMID 32434539): meta-analysis of 31 trials, 3,321 subjects, LDL 4.55 mg/dL and total cholesterol 4.66 mg/dL lower, no effect on HDL or triglycerides. Samavat et al. (Am J Clin Nutr, 2016; PMID 27806972): the largest extract trial at this record's dose, 936 postmenopausal women completing 12 months of 843 mg EGCG/day, NIH-funded; LDL fell 4.1 percent against a 0.9 percent rise on placebo, total cholesterol fell only in women starting at 200 mg/dL or above, and triglycerides rose 3.6 percent against a 2.5 percent fall on placebo. Against: Igho-Osagie et al. (J Nutr, 2020; PMID 33188386): meta-analysis of 14 short tea trials (4 to 24 weeks, 798 participants), no effect on blood pressure or any lipid, with the evidence rated low to moderate for lack of power. Blood pressure: Peng et al. (Sci Rep, 2014; PMID 25176280): 13 randomized controlled trials, systolic 1.98 mmHg lower and diastolic 1.92 mmHg lower, with the effect present only in low-dose polyphenol subgroups, which does not support the 400 to 800 mg dose framing for this endpoint. Glucose: Zheng et al. (Am J Clin Nutr, 2013; PMID 23426037): meta-analysis of 22 trials, 1,584 subjects, fasting glucose 1.48 mg/dL lower, no change in insulin, HbA1c or HOMA-IR. Hartley et al. (Cochrane Database Syst Rev, 2013; PMID 23780706): Cochrane review of green and black tea for primary prevention of cardiovascular disease, 11 trials, 821 participants; no trial reported cardiovascular events, and the green tea results were not stable to sensitivity analysis. Nagao et al. (Am J Clin Nutr, 2005; PMID 15640470): 35 men, 12 weeks of a tea drink containing 690 mg catechins, run by researchers at the company that makes the beverage; body fat fell and malondialdehyde-modified LDL moved with it; it did not measure LDL cholesterol and did not test an EGCG extract, so it is context, not evidence for this record. Safety: Dostal et al. (Food Chem Toxicol, 2015; PMID 26051348): the Minnesota trial's safety report, 1,075 women, ALT elevations in 6.7 percent on extract against 0.7 percent on placebo. Grade B (surrogate endpoints, replicated).
Why Grade B and not Grade A
Grade B reflects moderate human evidence -- typically a single strong trial, multiple smaller trials, or surrogate endpoint data without hard clinical outcome replication. To reach Grade A, EGCG (Epigallocatechin Gallate / Green Tea Extract) would require at least one additional independent randomized trial demonstrating a hard clinical endpoint or objectively measured functional outcome in a comparable population.
What this grade covers and what it does not
What would move this grade
An independent randomized trial demonstrating a hard clinical endpoint -- mortality, major adverse event, or objectively confirmed functional improvement -- in an adequately powered sample, with results independently replicated, would support Grade A.
How this was studied
Form: The one long trial used a green tea extract capsule supplement high in EGCG, taken as 4 capsules daily (Samavat 2016, PMID 27806972; Dostal 2015, PMID 26051348). The pooled analyses mixed green tea catechin or EGCG preparations with brewed green tea beverages and extracts (Kim 2011, PMID 22027055; Momose 2016, PMID 27324590; Zheng 2011, PMID 21715508; Xu 2020, PMID 32434539). · Dose: EGCG 107 to 856 mg/day in the EGCG-restricted review (Momose 2016, PMID 27324590) and total catechins 145 to 3,000 mg/day in the catechin review (Kim 2011, PMID 22027055); the 12-month trial gave 1,315 mg catechins (843 mg EGCG) daily (Samavat 2016, PMID 27806972; Dostal 2015, PMID 26051348). · Population: Healthy adults in the EGCG review, 17 trials and 1,356 subjects (Momose 2016, PMID 27324590); 14 to 31 trials and 1,136 to 3,321 adults in the lipid meta-analyses (Zheng 2011, PMID 21715508; Xu 2020, PMID 32434539); 22 trials and 1,584 adults for glucose (Zheng 2013, PMID 23426037); 1,075 healthy, predominantly Caucasian postmenopausal women randomized, 936 completing the lipid substudy (Samavat 2016, PMID 27806972; Dostal 2015, PMID 26051348). · Duration: 4 to 14 weeks in the EGCG review (Momose 2016, PMID 27324590) and 3 to 24 weeks in the catechin review (Kim 2011, PMID 22027055); 12 months in the single long extract trial (Samavat 2016, PMID 27806972).